Carl Icahn, Chairman of ImClone's Board of Directors stated: "We are extremely pleased to be able to present our stockholders with an offer that, if accepted, will bring them $70 per share in cash. I would like to thank the stockholders who have been supportive of me and the new directors who replaced the old regime."

"We came on board after a proxy contest and consent solicitation in which we criticized the old regime. Since then we were able to cut costs, substantially improve our relationship with Bristol-Myers Squibb and continue the expansion of the use of ERBITUX(R) in fighting certain cancers while developing what is a promising pipeline."

"We feel that the Eli Lilly transaction vindicates our decision to oppose in 2006 a potential transaction in which the Company would have been sold at approximately $36 per share which the prior board favored."

"Finally, I want to thank my fellow Board members and ImClone employees for their help in bringing this transaction to fruition. I especially want to acknowledge the roles of Alex Denner and Richard Mulligan, two Board members, for their yeoman service to ImClone after the proxy contest to help turn the Company around." Mr. Icahn concluded by stating that "while it is easy to hurl stones, all stockholders owe a debt of gratitude to Sam Waksal without whose dedication and perseverance neither ERBITUX nor our great pipeline would exist."

John H. Johnson, ImClone's Chief Executive Officer, said, "This combination delivers compelling and certain value to ImClone stockholders."

About ImClone Systems

ImClone Systems Incorporated is a fully integrated global biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The Company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systems' headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, New Jersey. For more information about ImClone Systems, please visit the Company's web site at http://www.imclone.com.

Important Information about the Press Release

The tender offer referred to in this press release has not commenced and this press release is neither an offer to buy nor invitation to purchase any securities, or an offer to sell any securities. This does not constitute a recommendation as to any tender offer nor does this communication constitute a solicitation of any vote or approval.

Investors and security holders are urged to read any disclosure documents filed with the SEC including any tender offer statement and ImClone Systems' recommendation when it is available because they contain important information. Investors and security holders will be able to obtain a free copy of the disclosure documents and recommendation (when they are available) and other documents filed with the SEC at the SEC's website at www.sec.gov or from ImClone Systems at its office at 180 Varick Street, New York, NY 10014

Forward Looking Information

Certain matters discussed in this news release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Federal securities laws. Although the Company believes that the expectations reflected in such forward-looking statements are based upon reasonable assumptions it can give no assurance that its expectations will be achieved. Forward-looking information is subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those currently expected. Many of these factors are beyond the Company's ability to control or predict. Important factors that may cause actual results to differ materially and could impact the Company and the statements contained in this news release can be found in the Company's filings with the Securities and Exchange Commission, particularly those factors identified as "risk factors" in the Company's most recent annual report of Form 10-K and in its quarterly reports on Form 10-Q and current reports on Form 8-K. For forward-looking statements in this news release, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The Company assumes no obligation to update or supplement any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: ImClone Systems Incorporated

ImClone Systems Incorporated 
Corporate Communications 
Tracy Henrikson, 908-243-9945 
MEDIA@IMCLONE.COM 
or 
Corporate Communications 
Rebecca Gregory, 646-638-5058

Key reasons to purchase this title

- Benchmark Bristol-Myers Squibbs performance against key rivals in the ethical pharmaceutical sector

- Assess the level of generic exposure faced by Bristol-Myers Squibb out to 2013, driven primarily by patent expiry for its lead product Plavix in 2011

- Analyze BMSs biologics-led growth strategy out to 2013, driven by its existing access to Erbitux and Orencia and new biologic launches also

Key Topics Covered:

- List Of Tables

- List of Figures

Companies Mentioned:

- 888 Holdings plc

- Abbott Laboratories

- ACR Group Inc

- ACS Motion Control Ltd

- AstraZeneca PLC

- Automatic Data Processing, Inc.

- Boehringer Ingelheim GmbH

- Bristol-Myers Squibb Company

- Daiichi Sankyo, Ltd.

- Eli Lilly and Company

- EMI Group PLC

- Gilead Sciences, Inc.

- GlaxoSmithKline Plc

- IMS Health

- Insight Communications Company, Inc.

- Johnson & Johnson

- Medarex Inc

- Merck & Co., Inc.

- Merck KGaA

- New York & Company, Inc.

- Novartis AG

- NYSE Euronext

- Pfizer Inc

- Sanofi-Aventis

- Wyeth

For more information visit http://www.researchandmarkets.com/research/b0de7d/bristolmyers_squi

Source: Datamonitor

CONTACT: Laura Wood, Senior Manager, Research and Markets Fax: +1 646 607 1907 (US) Fax: +353 1 481 1716 (Rest of World) e-mail: press@researchandmarkets.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Under the terms of the co-development and co-commercialization agreement of Erbitux in Japan, Merck Serono will distribute the product and record the sales for the collaboration. The terms of this agreement provide that Merck KGaA will receive 50% of the profit/loss from sales in Japan, and ImClone and Bristol-Myers Squibb will each receive 25%.

The sharing of profit/loss reflects the co-exclusive rights to Erbitux in Japan previously granted by ImClone to Merck KGaA and Bristol-Myers Squibb. In addition to its percentage of profits, ImClone will receive from Merck KGaA a 4.75% royalty of total net sales in Japan.

The co-development and co-commercialization agreement between ImClone, Bristol-Myers Squibb and Merck KGaA (along with the Japanese subsidiaries of Bristol-Myers Squibb and Merck Ltd) is for the joint development and marketing of Erbitux in Japan for the treatment of EGFR-expressing mCRC, as well as for the treatment of any other cancers the three companies agree to pursue.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall 
not be liable for errors or delays in the content, or for any actions 
taken in reliance thereon

Sign up to gain analyst insight for the above companies by following this link: http://maybachfinancial.com/?id=6&name=Register

Analyst reviews will be posted in the member's area of www.maybachfinancial.com under "Analyst Reviews."

Whether trading on the NYSE, Nasdaq, Amex, TSX or TSX-V, our experienced research team will investigate prime investment opportunities on behalf of the MaybachFinancial.com subscribers to offer a comprehensive look at what is happening and why. Sign up today at www.maybachfinancial.com for a free subscription.

Reports vary by sector and markets and look at various aspects of each company to provide an unbiased view and provide pertinent information so investors can make informed decisions regarding their portfolios.

Maybach Financial (Maybach) is not a registered broker dealer or a registered investment advisor. However, we do use information from licensed analysts. No information accessed through the Maybach Web site or this release constitutes a recommendation to buy, sell or hold any security in any jurisdiction. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein.

Analyst reviews may or may not contain all the information listed above as each opinion and review varies with each company reviewed.

Please view the full disclaimer: http://maybachfinancial.com/?id=20&name=Terms

SOURCE: MBF Financial